Subsequently, we developed a prognostic risk model based on CDKN1A, KLF2, and IFNG expression that significantly stratifies DLBCL patients into distinct risk groups, thereby potentially informing personalized treatment strategies. Here, CDKN1A is linked to diffuse large B-cell lymphoma.